Loading...
•
Jun 30
Xeris Biopharma Q2 2025 Earnings Report
Xeris Biopharma reported record financial results for the second quarter of 2025, driven by significant revenue growth across its product portfolio, and raised its full-year revenue guidance.
Key Takeaways
Xeris Biopharma achieved record financial results in Q2 2025, with total revenue increasing by 49% year-over-year to $71.5 million, primarily fueled by a 136% surge in Recorlev revenue. The company also raised its full-year 2025 revenue guidance, reflecting strong patient demand and confidence in continued growth.
Total revenue for Q2 2025 reached a record $71.5 million, marking a 48.8% increase year-over-year.
Recorlev revenue significantly grew by 135.7% to $31.4 million, driven by a 122% increase in the average number of patients.
The company raised its full-year 2025 total revenue guidance to $280-$290 million, up from the previous range of $260-$275 million.
Net loss for the quarter improved significantly by 87% to $1.9 million, or ($0.01) per share, compared to a $15.0 million net loss in the prior year.
Xeris Biopharma
Xeris Biopharma
Xeris Biopharma Revenue by Segment
Revenue by Segment
Recorlev Revenue
CapyFin.comGvoke Revenue
CapyFin.comKeveyis Revenue
CapyFin.comOther Product Revenue
CapyFin.comRoyalty, Contract & Other Revenue
CapyFin.com Forward Guidance
Xeris Biopharma raised its full-year 2025 total revenue guidance and provided a long-term outlook, projecting significant growth by 2030 and 2035, driven by its core products and pipeline.
Positive Outlook
- Full-year 2025 total revenue guidance raised to $280-$290 million from $260-$275 million.
- Long-term vision includes $750 million in total revenue by 2030.
- Recorlev is expected to reach nearly $1 billion in net revenue by 2035.
- XP-8121 has a potential peak net revenue of $1-$3 billion.
- Company is on an accelerated growth trajectory, building a platform for short and long-term value creation.